More specifically, undermining the eligibility of AβPP mRNA to serve as the amplification template is, apparently, a valid therapeutic strategy for AD (in its both, conventional and unconventional forms; this strategy, however, would not impact AACD). Here, APP is linked to Alzheimer disease.